[go: up one dir, main page]

WO1999015661A1 - Regulateur de la croissance cellulaire - Google Patents

Regulateur de la croissance cellulaire Download PDF

Info

Publication number
WO1999015661A1
WO1999015661A1 PCT/US1998/020001 US9820001W WO9915661A1 WO 1999015661 A1 WO1999015661 A1 WO 1999015661A1 US 9820001 W US9820001 W US 9820001W WO 9915661 A1 WO9915661 A1 WO 9915661A1
Authority
WO
WIPO (PCT)
Prior art keywords
celr
sequence
sequences
polynucleotide sequence
fragments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1998/020001
Other languages
English (en)
Inventor
Preeti Lal
Neil C. Corley
Purvi Shah
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Incyte Corp
Original Assignee
Incyte Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Pharmaceuticals Inc filed Critical Incyte Pharmaceuticals Inc
Priority to EP98953187A priority Critical patent/EP1015588A1/fr
Priority to JP2000512953A priority patent/JP2001517442A/ja
Priority to CA002304126A priority patent/CA2304126A1/fr
Priority to AU10621/99A priority patent/AU1062199A/en
Publication of WO1999015661A1 publication Critical patent/WO1999015661A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • CGR19 is a zinc-binding protein which contains a ring-finger domain close to its carboxy terminus In contrast to other ⁇ ng-finger-containing proteins, CGR19 lacks a ring- finger associated B-box domain (Madden et al., supra).
  • the ring-finger domain of CGR19 has a consensus sequence of C-X 2 -C-X (9 . 27) -C-X ( 1 _ 3) -H-X (2 _ 3) -C-X 2 -C-X (4 _ 4g) -C-X 2 -C for binding two zinc ions.
  • alleles are an alternative form of the gene encoding CELR. Alleles may result from at least one mutation in the nucleic acid sequence and may result in altered mRNAs or polypeptides whose structure or function may or may not be altered. Any given natural or recombinant gene may have none, one, or many allelic forms. Common mutational changes which give rise to alleles are generally ascribed to natural deletions, additions, or substitutions of nucleotides. Each of these types of changes may occur alone, or in combination with the others, one or more times in a given sequence.
  • negatively charged amino acids may include aspartic acid and glutamic acid: positively charged amino acids may include lysine and arginine: and amino acids with uncharged polar head groups having similar hydrophilicity values may include leucine, isoleucine, and valine, glycine and alanine. asparagine and glutamine. serine and threonine, and phenylalanine and tyrosine.
  • hybridization refers to any process by which a strand of nucleic acid binds with a complementary strand through base pairing.
  • “Fragments” are those nucleic acid sequences which are greater than 60 nucleotides than in length, and most preferably includes fragments that are at least 100 nucleotides or at least 1000 nucleotides, and at least 10,000 nucleotides in length.
  • the term “oiigonucleotide” refers to a nucleic acid sequence of at least about 6 nucleotides to about 60 nucleotides, preferably about 15 to 30 nucleotides, and more preferably about 20 to 25 nucleotides, which can be used in PCR amplification or a hybridization assay, or a microarray. As used herein, oiigonucleotide is substantially equivalent to the terms “amplimers”, “primers”, “oligomers”, and “probes”, as commonly defined in the art.
  • portion refers to fragments of that protein.
  • the fragments may range in size from five amino acid residues to the entire amino acid sequence minus one amino acid.
  • a protein "comprising at least a portion of the amino acid sequence of SEQ ID NO: 1" encompasses the full-length CELR and fragments thereof.
  • binding refers to that interaction between a protein or peptide and an agonist, an antibody and an antagonist. The interaction is dependent upon the presence of a particular structure (i.e., the antigenic determinant or epitope) of the protein recognized by the binding molecule. For example, if an antibody is specific for epitope "A", the presence of a protein containing epitope A (or free, unlabeled A) in a reaction containing labeled "A" and the antibody will reduce the amount of labeled A bound to the antibody.
  • Numerous equivalent conditions comprising either low or high stringency depend on factors such as the length and nature of the sequence (DNA, RNA, base composition), nature of the target (DNA, RNA, base composition), milieu (in solution or immobilized on a solid substrate), concentration of salts and other components (e.g., formamide, dextran sulfate and/or polyethylene glycol), and temperature of the reactions (within a range from about 5°C below the melting temperature of the probe to about 20°C to 25°C below the melting temperature).
  • concentration of salts and other components e.g., formamide, dextran sulfate and/or polyethylene glycol
  • temperature of the reactions within a range from about 5°C below the melting temperature of the probe to about 20°C to 25°C below the melting temperature.
  • One or more factors be may be varied to generate conditions of either low or high stringency different from, but equivalent to, the above listed conditions.
  • substantially purified refers to nucleic or amino acid sequences that are removed from their natural environment, isolated or separated, and are at least 60% free, preferably 75% free, and most preferably 90% free from other components with which they are naturally associated.
  • a pharmaceutical composition comprising purified CELR may be administered to a subject to prevent or treat a disorder associated with cell proliferation including, but not limited to, the types of cancer listed above.
  • compositions for oral administration can be formulated using pharmaceutically acceptable carriers well known in the art in dosages suitable for oral administration.
  • Such carriers enable the pharmaceutical compositions to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions, and the like, for ingestion by the patient.
  • Fluorescent in situ hybridization FISH as described in Verma et al (1988) Human Chromosomes A Manual of Basic Techniques. Pergamon Press, New York, NY
  • FISH Fluorescent in situ hybridization
  • OMIM Online Mendehan Inheritance in Man
  • Step 5 Repeat steps 2-4 for an additional 29 cycles Step 6 72° C for 180 sec
  • the microarray is washed to remove nonhybridized probes, and a scanner is used to determine the levels and patterns of fluorescence. The scanned images are examined to determine degree of complementarity and the relative abundance of each oiigonucleotide sequence on the micro-array.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

L'invention concerne un régulateur de la croissance cellulaire humaine (CELR) et des polynucléotides qui identifient et codent CELR. Elle porte aussi sur des vecteurs d'expression, des cellules hôtes, des agonistes et des antagonistes, ainsi que sur des méthodes de traitement de troubles associés à l'expression de CELR.
PCT/US1998/020001 1997-09-22 1998-09-22 Regulateur de la croissance cellulaire Ceased WO1999015661A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP98953187A EP1015588A1 (fr) 1997-09-22 1998-09-22 Regulateur de la croissance cellulaire
JP2000512953A JP2001517442A (ja) 1997-09-22 1998-09-22 細胞増殖調節因子
CA002304126A CA2304126A1 (fr) 1997-09-22 1998-09-22 Regulateur de la croissance cellulaire
AU10621/99A AU1062199A (en) 1997-09-22 1998-09-22 Cell growth regulator

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93484597A 1997-09-22 1997-09-22
US08/934,845 1997-09-22

Publications (1)

Publication Number Publication Date
WO1999015661A1 true WO1999015661A1 (fr) 1999-04-01

Family

ID=25466171

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/020001 Ceased WO1999015661A1 (fr) 1997-09-22 1998-09-22 Regulateur de la croissance cellulaire

Country Status (5)

Country Link
EP (1) EP1015588A1 (fr)
JP (1) JP2001517442A (fr)
AU (1) AU1062199A (fr)
CA (1) CA2304126A1 (fr)
WO (1) WO1999015661A1 (fr)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997045542A2 (fr) * 1996-05-29 1997-12-04 Genzyme Corporation Genes regulateurs de la croissance cellulaire

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997045542A2 (fr) * 1996-05-29 1997-12-04 Genzyme Corporation Genes regulateurs de la croissance cellulaire

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
"Human cell growth regulaor CGR19 mRNA (accession number U66469)", EMBL DATABASE, 19 January 1997 (1997-01-19) *
HILLIER L ET AL.: "Homo sapiens cDNA clone 325902 (accession no. AA037263)", EMBL DATABASE, 28 August 1996 (1996-08-28), Heidelberg, Germany, XP002092659 *
HILLIER L ET AL.: "Homo sapiens cDNA clone 417361 (accession no. W88447)", EMBL DATABASE, 7 July 1996 (1996-07-07), Heidelberg, Germany, XP002092660 *
MADDEN S L ET AL: "INDUCTION OF CELL GROWTH REGULATORY GENES BY P53", CANCER RESEARCH, vol. 56, no. 23, 1 December 1996 (1996-12-01), pages 5384 - 5390, XP002046025 *

Also Published As

Publication number Publication date
JP2001517442A (ja) 2001-10-09
CA2304126A1 (fr) 1999-04-01
EP1015588A1 (fr) 2000-07-05
AU1062199A (en) 1999-04-12

Similar Documents

Publication Publication Date Title
US5849528A (en) Polynucleotides encoding a human S100 protein
US5888792A (en) ATP-dependent RNA helicase protein
US5866119A (en) Human ribonuclease
US5871973A (en) Cell division regulators
US5874248A (en) Glutathione S-transferase homolog
US6265550B1 (en) Insulin receptor tyrosine kinase substrate
WO1999023220A1 (fr) Suppresseur de la signalisation cytokinaire
US5869259A (en) Carboxypeptidase inhibitor
US5858717A (en) Human formin binding protein
US5871971A (en) Human developmentally regulated GTP-binding protein
US5858714A (en) Human metaxin protein
US5863766A (en) Human sigma receptor
US7947804B1 (en) Vesicle trafficking proteins
US6527689B1 (en) Maternally transcribed protein
US5919661A (en) Polynucleotides encoding cytokine inducible regulatory protein
US5914249A (en) Cell-cycle phosphoproteins
US6326158B1 (en) SH3-containing proteins
US6077688A (en) Transducin beta-1 subunit
US5932443A (en) Human antigens
WO1999015554A2 (fr) Proteine de type ras
US6677126B2 (en) Antibody for human translational regulator
WO1999019483A1 (fr) Proteine de type p23 de complexe de recepteur de progesterone humain
EP1015588A1 (fr) Regulateur de la croissance cellulaire
WO1998055616A2 (fr) Proteine associee au site brca2
EP1086234A1 (fr) Nouvel inhibiteur de carboxypeptidase d'origine humaine

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 512953

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref document number: 2304126

Country of ref document: CA

Ref country code: CA

Ref document number: 2304126

Kind code of ref document: A

Format of ref document f/p: F

NENP Non-entry into the national phase

Ref country code: KR

WWE Wipo information: entry into national phase

Ref document number: 1998953187

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1998953187

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1998953187

Country of ref document: EP